[CYCCP] Cyclacel Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 6.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CYCCP

Refresh chart

Description: Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company?s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatmen

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10.38 M Cash From Investing Activities10 K Cash From Operating Activities-4.9 M Gross Profit
Net Profit-4.91 M Operating Profit-5.3 M Total Assets35.36 M Total Current Assets35.02 M
Total Current Liabilities8.14 M Total Debt Total Liabilities8.33 M Total Revenue510 K
Technical Data
High 52 week6.45 Low 52 week4.22 Last close4.76 Last change-9.44%
RSI57.94 Average true range0.25 Beta0.23 Volume
Simple moving average 20 days-2% Simple moving average 50 days-2.27% Simple moving average 200 days-9.89%
Performance Data
Performance Week0.82% Performance Month-4.49% Performance Quart-6.87% Performance Half2.22%
Performance Year-15.59% Performance Year-to-date-19.63% Volatility daily5.33% Volatility weekly11.92%
Volatility monthly24.42% Volatility yearly84.61% Relative Volume0% Average Volume463.48
New High New Low

News

2019-08-13 16:05:00 | Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results

2019-08-11 15:46:20 | The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

2019-08-07 07:00:00 | Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results

2019-07-22 07:00:00 | Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

2019-05-14 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results

2019-05-08 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results

2019-04-01 07:00:00 | Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

2019-03-27 16:05:00 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-26 12:46:27 | Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

2019-03-25 07:00:00 | Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

2019-03-20 07:00:00 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

2019-03-13 07:00:00 | Cyclacel to Participate in 31st Annual ROTH Conference March 18-19

2019-03-05 07:00:00 | Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019

2019-02-05 07:00:00 | Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

2019-01-07 07:00:00 | Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019

2018-12-27 07:00:00 | Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

2018-11-12 16:05:00 | Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-06 07:00:00 | Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

2018-10-23 07:00:00 | Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

2018-10-04 07:00:00 | Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

2018-09-26 07:00:00 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference

2018-09-12 07:00:00 | Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors

2018-09-10 07:00:00 | Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

2018-08-29 07:00:00 | Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference

2018-08-09 16:05:00 | Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-01 07:00:00 | Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results

2018-05-14 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results

2018-05-08 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results

2018-04-17 09:00:00 | Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

2018-04-16 07:00:00 | Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

2018-03-28 16:05:00 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

2018-03-21 07:00:00 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results

2018-03-15 07:00:00 | Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting

2018-03-06 07:19:56 | Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference

2018-02-21 07:00:00 | Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

2018-02-06 07:00:00 | Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

2018-01-24 07:00:00 | Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference

2018-01-09 07:00:00 | Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018

2017-12-12 07:00:00 | Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting

2017-11-09 16:05:00 | Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

2017-11-02 07:00:00 | Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results

2017-11-01 09:02:00 | Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting

2017-09-21 07:00:00 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

2017-09-08 07:00:00 | Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

2017-08-09 16:05:00 | Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 

2017-08-07 07:00:00 | Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

2017-08-02 07:00:00 | Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results

2017-07-21 14:00:00 | Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

2017-05-11 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results

2017-05-05 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results